B

Epidemiological data indicates that tobacco smokers exhibit a significantly lower statistical risk of developing Parkinson's disease, and a large-scale prospective study has pointed to an unexpected underlying mechanism. Investigating this paradox, medical researchers at the University of Oxford monitored a cohort of 512,701 adults in China over a 12-year follow-up period. At the baseline of the study, investigators recorded the concentrations of exhaled carbon monoxide (CO) in the participants' breath. While carbon monoxide is widely recognized as a hazardous gas present in cigarette smoke, the human body naturally generates minute quantities of it to serve as an endogenous signaling molecule. Throughout the tracking period, a total of 1,131 participants were diagnosed with Parkinson's disease. Confirming trends observed in historical literature, active tobacco smokers in the cohort demonstrated an approximate 30% reduction in relative risk. However, a highly surprising discovery emerged among the segment of participants who had never smoked in their lives. Non-smokers who naturally exhaled higher baseline concentrations of carbon monoxide were roughly one-third less likely to develop Parkinson's disease than peers with the lowest exhaled concentrations. This inverse relationship proved highly specific, as no similar correlation was observed for other neurodegenerative conditions. Crucially, these findings must not be misinterpreted as an endorsement of tobacco use, and smoking should never be adopted as a preventative strategy against Parkinson's disease. Tobacco use causes devastating health outcomes, including various cancers, ischemic heart disease, and strokes, meaning its severe physical harms drastically outweigh any isolated statistical correlations. Instead, this research provides a vital biological clue for future therapeutic development. If low, controlled doses of carbon monoxide can successfully mitigate neuroinflammation and cellular stress as laboratory models suggest, pharmacological experts may eventually synthesize safe, regulated CO-based treatments. In fact, an initial early-phase clinical trial evaluating a low-dose carbon monoxide drug in Parkinson's disease patients has already commenced at Harvard. Because this project was entirely observational in nature, it definitively proves a statistical correlation rather than providing absolute medical proof that carbon monoxide exerts a direct neuroprotective effect. [Bueno-Lopez, C., Iona, A., Turnbull, I., et al. (2026). Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease. JAMA Neurology, 83(11). DOI: 10.1001/jamaneurol.2026.3037]